FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul Scigalla

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Procedures

Co-author Network

Publications

TOP 3
Beate Schultheis; Paul Scigalla; Dirk Strumberg; Jochen Schuette; Lothar Bergmann; Ullrich Graeven; Axel-Rainer Hanauske; Rainer Lipp; K Saito; Max E Scheulen
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Wanja M Bernhardt; Michael S Wiesener; Paul Scigalla; James Chou; Roland E Schmieder; Volkmar Günzler; Kai-Uwe Eckardt
Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.
Andrzej Więcek; Islah Ahmed; Paul Scigalla; Rossen Koytchev
Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul Scigalla (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Beate Schultheis; Paul Scigalla; Dirk Strumberg; Jochen Schuette; Lothar Bergmann; Ullrich Graeven; Axel-Rainer Hanauske; Rainer Lipp; K Saito; Max E Scheulen
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Investigational new drugs 2012;30(3):1184-92.
2010: Wanja M Bernhardt; Michael S Wiesener; Paul Scigalla; James Chou; Roland E Schmieder; Volkmar Günzler; Kai-Uwe Eckardt
Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.
Journal of the American Society of Nephrology : JASN 2010;21(12):2151-6.
2010: Andrzej Więcek; Islah Ahmed; Paul Scigalla; Rossen Koytchev
Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
Advances in therapy 2010;27(12):941-52.
2008: Stefan Krivoshiev; Vasil V Todorov; Jacek Manitius; Stanislaw Czekalski; Paul Scigalla; Rossen Koytchev
Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.
Current medical research and opinion 2008;24(5):1407-15.
2008: Volker Wizemann; Boleslaw Rutkowski; Conrad Baldamus; Paul Scigalla; Rossen Koytchev
Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Current medical research and opinion 2008;24(3):625-37.
2006: Marc Salzberg; Miklos Pless; Christoph Rochlitz; Klara Ambrus; Paul Scigalla; Richard Herrmann
A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
Investigational new drugs 2006;24(4):299-304.
2006: Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta M Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):25-35.
2005: Gunter Schuch; Maike de Wit; Jan Höltje; Eckart Laack; Georgia Schilling; Dieter K Hossfeld; Walter Fiedler; Paul Scigalla; Mark S Jacobs
Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3624-6.
2005: Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood 2005;105(3):986-93.
2004: Srinivasan Madhusudan; Gaël Deplanque; Jeremy P Braybrooke; Emma Cattell; Marian Taylor; Pat Price; Marie D Tsaloumas; Niall Moore; Susan M Huson; Chris Adams; Peggy Frith; Paul Scigalla; Adrian L Harris
Antiangiogenic therapy for von Hippel-Lindau disease.
JAMA : the journal of the American Medical Association 2004;291(8):943-4.
2003: Anne-Marie O'Farrell; James M Foran; Walter Fiedler; Hubert Serve; Ronald L Paquette; Maureen A Cooper; Helene A Yuen; Sharianne G Louie; Heidi Kim; Susan Nicholas; Michael C Heinrich; Wolfgang E Berdel; Carlo Bello; Mark Jacobs; Paul Scigalla; William C Manning; Stephen Kelsey; Julie M Cherrington
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5465-76.
2003: Walter Fiedler; Rolf M Mesters; Heike Tinnefeld; Sonja Loges; Peter Staib; Ulrich Duhrsen; Michael Flasshove; Oliver G Ottmann; Wolfram Jung; Franco Cavalli; Rolf Kuse; Joerg Thomalla; Hubert Serve; Anne-Marie O'Farrell; Mark Jacobs; Nicoletta M Brega; Paul Scigalla; Dieter K Hossfeld; Wolfgang E Berdel
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Blood 2003;102(8):2763-7.
2003: Jean-Francois GIRMENS; Ali Erginay; Pascale Massin; Paul Scigalla; alain gaudric; Stéphane Richard
Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
American journal of ophthalmology 2003;136(1):194-6.
2003: Bart C Kuenen; Josep Tabernero; Jose Baselga; Franco Cavalli; Elisabeth Pfanner; Pier Franco Conte; Siegfried Seeber; Srinivasan Madhusudan; Gael Deplanque; Holgen Huisman; Paul Scigalla; Klaas Hoekman; Adrian L Harris
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1648-55.
2002: Stéphane Richard; Laure Croisille; Jeannine Yvart; Nicole Casadeval; Pascal Eschwège; Nozar Aghakhani; Philippe David; alain gaudric; Paul Scigalla; Olivier Hermine
Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy.
Blood 2002;99(10):3851-3.
2002: Bart C Kuenen; Lee Rosen; Egbert F Smit; Mandy R N Parson; Marcel Levi; Rita Ruijter; Holger Huisman; Marc A Kedde; Paul Noordhuis; Wim J F van der Vijgh; Godefridus J Peters; Gillian F Cropp; Paul Scigalla; Klaas Hoekman; HERBERT PINEDO; Giuseppe Giaccone
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1657-67.
2002: Aleksandar Sikole; Momir Polenakovic; Vera Spiroska; Biljana Polenakovic; Horst Klinkmann; Paul Scigalla
Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy.
Artificial organs 2002;26(2):98-102.
2001: Rolf M Mesters; Teresa Padró; Ralf Bieker; Martin B Steins; Michael Kreuter; M Göner; S Kelsey; Paul Scigalla; Walter Fiedler; Thomas Büchner; Wolfgang E Berdel
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.
Blood 2001;98(1):241-3.